Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2000
06/22/2000CA2353997A1 Therapeutic and diagnostic uses of protein tyrosine phosphatase tc-ptp
06/22/2000CA2353924A1 Cyclic hydrazine derivatives as tnf-alpha inhibitors
06/22/2000CA2353897A1 1,4-benzodiazepinone derivatives and their use as integrin antagonists
06/22/2000CA2353866A1 Treatment of papillomavirus infections
06/22/2000CA2353593A1 Method of administering a compound to multi-drug resistant cells
06/22/2000CA2353151A1 Substituted aryl and heteroaryl derivatives, the preparation thereof and their use as medicaments
06/22/2000CA2352613A1 New pharmaceutical formulation
06/22/2000CA2352337A1 22s-hydroxycholesta-8, 14-diene derivatives with meiosis regulating activity
06/22/2000CA2352079A1 Amido polybiguanides and the use thereof as antimicrobial agents
06/22/2000CA2351860A1 Piperazine ethylamide derivatives with 5-ht1a receptor activity
06/22/2000CA2351859A1 1,4-piperazine derivatives having 5ht1a receptor activity
06/22/2000CA2351726A1 Hcg therapy for the treatment of breast cancer
06/22/2000CA2351469A1 Method and composition for the maintenance and restitution of gut integrity
06/22/2000CA2351464A1 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
06/22/2000CA2351400A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine urea derivatives having 5ht1a receptor activity
06/22/2000CA2351385A1 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one derivates being 5ht2c agonists
06/22/2000CA2349501A1 Quinolone vitronectin receptor antagonist pharmaceuticals
06/22/2000CA2347922A1 Vanadium compounds for treating cancer
06/22/2000CA2347770A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
06/22/2000CA2346684A1 Use of a mek inhibitor for preventing transplant rejection
06/22/2000CA2346448A1 Treatment of arthritis with mek inhibitors
06/22/2000CA2345752A1 Tricyclic nitrogen heterocycles as pde iv inhibitors
06/22/2000CA2293023A1 Process for producing ucn-01
06/22/2000CA2292874A1 Treatment of hereditary diseases with gentamicin
06/22/2000CA2289422A1 Process and intermediates for preparing 5-lipoxygenase inhibitors
06/22/2000CA2256855A1 Treatment of hereditary diseases with gentamicin
06/21/2000EP1010701A1 Process for the preparation of 3-cephem compounds
06/21/2000EP1010699A1 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivatives
06/21/2000EP1010698A1 1,2-dithiolane derivatives, their process of preparation and pharmaceutical compositions containing them
06/21/2000EP1010694A2 Spiroimidazoline derivatives and their use as alpha2-adrenergic antagonists and monoamines-reuptake blockers
06/21/2000EP1010693A1 Imidazoline derivatives, preparation and pharmaceutical compositions containing them
06/21/2000EP1010691A2 Hydrazide derivatives, process for their preparation and pharmaceutical compositions containing them
06/21/2000EP1010689A1 Substituted cycloheptenes, their preparation and use
06/21/2000EP1010688A1 Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
06/21/2000EP1010429A2 Pharmaceutical composition, in particular for dietetical use comprising a derivative of pyruvic acid and unripe bitter orange extract
06/21/2000EP1010427A1 Proline-, glycine- and lysine-based pharmaceutical composition useful in dental treatment both in injectable form and in a formulation for topical use
06/21/2000EP1010426A1 Immunosuppression by photochemotherapy
06/21/2000EP1010425A1 Remedies for irritable bowel syndrome
06/21/2000EP1010424A1 Liver fat accumulation inhibitory composition, food additive for liver fat accumulation inhibition, and method of inhibiting liver fat accumulation
06/21/2000EP1010423A2 Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production
06/21/2000EP1010374A1 Fibre blend for enteral composition
06/21/2000EP1009860A1 Antisense oligonucleotide inhibition of ras
06/21/2000EP1009854A1 A method of treating cancer
06/21/2000EP1009846A1 Alphavirus-derived vectors useful as vaccines providing protection against paramyxovirus infection
06/21/2000EP1009831A2 Agonist antibodies to the thrombopoietin receptor, and their therapeutic uses
06/21/2000EP1009823A1 Human papilloma virus inhibition by antisense oligonucleotides
06/21/2000EP1009822A1 Antisense treatment of pulmonary hypertension
06/21/2000EP1009811A2 New tissue-specific calpaines, their production and their use
06/21/2000EP1009770A1 Peptides containing an arginine mimetic for the treatment of bone metabolic disorders, their production, and drugs containing these compounds
06/21/2000EP1009768A1 Persephin and related growth factors
06/21/2000EP1009763A1 Synthetic hepatitis c genes
06/21/2000EP1009760A2 Peroxisome-associated polypeptide, nucleotide sequence encoding said polypeptide and their uses in the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders
06/21/2000EP1009755A1 Steroid sulfatase inhibitors and methods for making and using the same
06/21/2000EP1009753A1 Hypoxia-regulated genes
06/21/2000EP1009752A1 Novel molecules of the tango-77 related protein family and uses thereof
06/21/2000EP1009750A1 Novel (alpha-aminophosphino) peptide derivatives, method for making same and therapeutic applications thereof
06/21/2000EP1009748A1 3-ALKYLPYRROLO 3,2-$i(c)]QUINOLINE DERIVATIVES
06/21/2000EP1009747A1 Ureido and thioureido derivatives of 4-amino-2(5h)-furanones and 4-amino-2(5h)-thiophenones as antitumor agents
06/21/2000EP1009743A1 Certain benzothiazine dioxide endothelin antagonists and processes for their preparation
06/21/2000EP1009742A1 5,5-disubstituted-1,5-dihydro-4,1-benzoxazepin-2(3h)-ones useful as hiv reverse transcriptase inhibitors
06/21/2000EP1009741A1 Novel carboxylic acid derivatives, their production and their use as mixed et a?/et b? endothelin-receptor antagonists
06/21/2000EP1009740A1 Methods and compositions for treating polycystic ovary syndrome
06/21/2000EP1009739A2 Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
06/21/2000EP1009738A1 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
06/21/2000EP1009737A2 Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
06/21/2000EP1009736A1 Malonic acid based matrix metalloproteinase inhibitors
06/21/2000EP1009734A1 Branched chain fatty acids, their derivatives and use in the treatment of central nervous system disorders
06/21/2000EP1009732A2 1-amino-alkylcyclohexane nmda receptor antagonists
06/21/2000EP1009730A1 New pentaerythritol derivatives, their production and use and intermediates for their synthesis
06/21/2000EP1009715A1 Improved method for preparing low-concentration polyaluminosilicate microgels
06/21/2000EP1009452A1 Dialysis solutions containing water soluble vitamins and nutrients
06/21/2000EP1009451A2 Methods and compositions to prevent formation of adhesions in biological tissues
06/21/2000EP1009440A1 Method for inhibiting immunostimulatory dna associated responses
06/21/2000EP1009439A1 Polymer-platinum compounds
06/21/2000EP1009437A1 Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
06/21/2000EP1009436A2 Acridine derivative for increasing the oral bioavailability of taxanes
06/21/2000EP1009426A1 Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase
06/21/2000EP1009424A2 Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto
06/21/2000EP1009420A1 Conjugates useful in the treatment of prostate cancer
06/21/2000EP1009417A1 Dietary supplements containing natural ingredients
06/21/2000EP1009416A1 Weight control composition comprising hypericum perforatum
06/21/2000EP1009415A1 INHIBITORS OF $g(b)-LACTAMASES AND USES THEREFOR
06/21/2000EP1009414A2 Novel pharmaceutical composition
06/21/2000EP1009413A2 Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
06/21/2000EP1009412A1 Use of purine nucleosides for modulating the axonal outgrowth of central nervous system neurons
06/21/2000EP1009411A1 Method and composition for treating sleep apnea
06/21/2000EP1009409A1 Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate
06/21/2000EP1009408A1 New combination of antiasthma medicaments
06/21/2000EP1009407A2 Noribogaine in the treatment of pain and drug addiction
06/21/2000EP1009405A1 Pyrrolidine and piperidine modulators of chemokine receptor activity
06/21/2000EP1009403A1 Method for treating schizophrenia
06/21/2000EP1009402A4 Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
06/21/2000EP1009402A1 Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
06/21/2000EP1009401A1 Dithiolopyrrolones and their corresponding monoxides and dioxides as antineoplastic agents
06/21/2000EP1009400A1 Combination therapy comprising atorvastatin and an antihypertensive agent
06/21/2000EP1009399A1 Gaba analogs to prevent and treat gastrointestinal damage
06/21/2000EP1009398A1 Molecular complex and control-release of alpha hydroxyacids
06/21/2000EP1009397A2 N,n-bis (phenylcarbamoylmethyl) dimethylammonium chloride and derivatives in the treatment of pain
06/21/2000EP1009396A1 Pharmaceutical formulation comprising a 2-aminoacetamide derivative and an ion exchange resin
06/21/2000EP1009394A1 New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising formoterol
1 ... 6296 6297 6298 6299 6300 6301 6302 6303 6304 6305 6306 6307 6308 6309 6310 6311 6312 6313 6314 6315 6316 ... 7860